Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 5Sarcoma 2Other hematologic neoplasm 2Gynecologic 2Genitourinary 2CNS 2NET 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 143Carcinoma, Neuroendocrine 56Thyroid Cancer, Papillary 54Pheochromocytoma 50Thyroid Neoplasms 41Paraganglioma 41Pituitary Neoplasms 37Adrenocortical Carcinoma 31Neoplasms 30Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 23Small Cell Lung Carcinoma 21Lung Neoplasms 21Carcinoid Tumor 20Sarcoma 19Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Prostatic Neoplasms 15Pancreatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Adrenal Gland Neoplasms 15Adenocarcinoma, Follicular 15

Interventions

Tirapazamine 1Ethiodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Endocrine × 1 year × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡